• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On January 14th, Goldman Sachs issued a research report giving China Biopharmaceutical (01177.HK) a "Buy" rating with a target price of HK$6.19. This target price is based on a 12-month sum-of-the-parts valuation method, where the innovative drug pipeline is valued at RMB 69.3 billion using a discounted cash flow method, while the generic drug business is valued at RMB 46.8 billion based on a P/E ratio of 12 and a five-year CAGR of 5%. China Biopharmaceutical announced the acquisition of 100% equity in Hergia for a total price of RMB 1.2 billion, with approximately RMB 1.1 billion paid in cash and the remaining RMB 97 million to be paid in installments through new shares. Hergia is a clinical-stage biotechnology company focusing on siRNA technology, currently possessing four clinical-stage projects targeting Lp(a), ApoC3, THRbeta, and HBV, and more than 10 preclinical candidate products. This is the third acquisition by China Biopharmaceutical in two years. Goldman Sachs believes that as siRNA technology gradually becomes an important innovative model for the treatment of chronic diseases, this acquisition will strengthen China Biopharmaceuticals R&D pipeline in the fields of cardiovascular, metabolic and liver diseases, and create synergies with its existing products.According to the General Administration of Customs, China imported 9,951.6 tons of rare earths in December, compared with 5,221 tons in November.According to the General Administration of Customs, China imported 101,062 tons of rare earths from January to December.According to the General Administration of Customs, China imported 13.448 million tons of natural gas in December, compared with 11.947 million tons in November.According to the General Administration of Customs, China imported 127.865 million tons of natural gas from January to December.

Gold Recovers As Fed Minutes Confirm Forecasts

Charlie Brooks

May 26, 2022 09:36

G1.png


Gold recouped some of its losses on Wednesday as minutes from a Federal Reserve meeting indicated that the central bank would maintain its plan to raise interest rates by a half-point at its June and July meetings.


At 4:15 p.m. ET (2015 GMT), spot gold declined 0.7% to $1,853.80 per ounce, after falling 1.3% to $1,844.49 earlier in the session. Gold futures in the U.S. closed down almost 1 percent at $1,846.3.


According to the minutes of the Federal Reserve's policy meeting on 3-4 May, all participants supported a half-percentage-point rate hike to battle inflation that threatened to surge without central bank intervention.


After the minutes were released, gold reduced losses, but remained down, having been lower for the majority of the day due to a higher dollar.


While the Fed minutes were mostly in line with market expectations, the Fed did indicate that 50 basis point hikes would likely be appropriate for the June and July meetings, according to Standard Chartered analyst Suki Cooper (OTC:SCBFF). The market will likely continue to focus on inflation data and indications of reducing cost pressures.


Even while gold is commonly viewed as a hedge against inflation, rate rises diminish its attractiveness since they tend to increase bond rates, increasing the opportunity cost of keeping zero-yield metal.


Christine Lagarde, president of the European Central Bank, has secured critical allies for her proposal to lift rates out of negative territory this summer.


Spot silver lost 0.5% to $21.99 per ounce, platinum fell 0.6% to $948.95 per ounce, while palladium climbed 0.1% to $2,002.22 per ounce.


Analysts at Commerzbank (ETR:CBKG) wrote in a note, "Platinum and palladium are being restrained by the continued challenges in the automobile industry, which is dampening demand for these precious metals."